Cesca Therapeutics (KOOL) shares have surged in early trading today after the company provided an update on the status of the FDA's review of its Investigational Device Exemption Supplement for a phase III pivotal trial, designed to demonstrate the safety and effectiveness of the company's SurgWerks system for the treatment of late stage, no option, critical limb ischemia patients.